NASDAQ:SNGX - Soligenix, Inc. Common Stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.15 +0.03 (+2.68 %)
(As of 07/20/2018 08:00 AM ET)
Previous Close$1.12
Today's Range$1.09 - $1.20
52-Week Range$0.91 - $3.70
Volume224,200 shs
Average Volume259,378 shs
Market Capitalization$9.80 million
P/E RatioN/A
Dividend YieldN/A
Soligenix, Inc. Common Stock logoSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio2.16
Quick Ratio2.16


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.43 million
Price / Sales1.85
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book1.60


EPS (Most Recent Fiscal Year)N/A
Net Income$-7,140,000.00
Net Margins-149.71%
Return on Equity-182.10%
Return on Assets-105.34%


Outstanding Shares8,750,000
Market Cap$9.80

Soligenix, Inc. Common Stock (NASDAQ:SNGX) Frequently Asked Questions

What is Soligenix, Inc. Common Stock's stock symbol?

Soligenix, Inc. Common Stock trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix, Inc. Common Stock's earnings last quarter?

Soligenix, Inc. Common Stock (NASDAQ:SNGX) issued its earnings results on Friday, May, 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter. Soligenix, Inc. Common Stock had a negative net margin of 149.71% and a negative return on equity of 182.10%. View Soligenix, Inc. Common Stock's Earnings History.

When is Soligenix, Inc. Common Stock's next earnings date?

Soligenix, Inc. Common Stock is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Soligenix, Inc. Common Stock.

What price target have analysts set for SNGX?

2 analysts have issued 12 month price targets for Soligenix, Inc. Common Stock's shares. Their predictions range from $3.00 to $5.00. On average, they anticipate Soligenix, Inc. Common Stock's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 247.8% from the stock's current price. View Analyst Ratings for Soligenix, Inc. Common Stock.

What is the consensus analysts' recommendation for Soligenix, Inc. Common Stock?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix, Inc. Common Stock in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Soligenix, Inc. Common Stock?

Soligenix, Inc. Common Stock saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 931,279 shares, an increase of 74.6% from the June 15th total of 533,338 shares. Based on an average daily volume of 290,174 shares, the short-interest ratio is presently 3.2 days. Currently, 16.1% of the company's stock are short sold. View Soligenix, Inc. Common Stock's Current Options Chain.

Who are some of Soligenix, Inc. Common Stock's key competitors?

Who are Soligenix, Inc. Common Stock's key executives?

Soligenix, Inc. Common Stock's management team includes the folowing people:
  • Dr. Christopher J. Schaber, Pres, CEO & Chairman (Age 52)
  • Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 64)
  • Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 46)
  • Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 66)
  • Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs

Has Soligenix, Inc. Common Stock been receiving favorable news coverage?

Media headlines about SNGX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Soligenix, Inc. Common Stock earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Soligenix, Inc. Common Stock?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix, Inc. Common Stock's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.15.

How big of a company is Soligenix, Inc. Common Stock?

Soligenix, Inc. Common Stock has a market capitalization of $9.80 million and generates $5.43 million in revenue each year. Soligenix, Inc. Common Stock employs 18 workers across the globe.

How can I contact Soligenix, Inc. Common Stock?

Soligenix, Inc. Common Stock's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

MarketBeat Community Rating for Soligenix, Inc. Common Stock (NASDAQ SNGX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Soligenix, Inc. Common Stock and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.